Director/PDMR Shareholding

RNS Number : 2492A

Creo Medical Group PLC

22 December 2017

 

Creo Medical Group plc (the "Company")

Director/PDMR Dealing

The Company announces that it has received notice of exercise of options ("Options") under the Company's EMI Share Option Scheme from Steven Morris, Chief Operating Officer, a PDMR, to subscribe for 115,000 Ordinary Shares of £0.001 each in the Company (the "New Ordinary Shares").  The exercise price of the Options is 15.56 pence each.

Following the exercise of these Options Mr Morris will hold 115,000 Ordinary Shares in the Company representing approximately 0.1423 per cent. of the Company's issued share capital.

Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on or around 3 January 2018.

Following the issue of the New Ordinary Shares the Company's total issued share capital will consist of 80,826,745 Ordinary Shares. The Company does not hold any Ordinary Shares in Treasury.  Therefore, following the issue of the New Ordinary Shares the total number of voting rights in the Company is 80,826,745.  This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Steven Morris
2	Reason for the notification
a)	Position/status	Chief Operating Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.001 each GB00BZ1BLL44
b)	Nature of the transaction	Exercise of shares options
c)	Price(s) and volume(s)	Price(s) Volume(s) Exercise of shares options at 15.56p per share 115,000
d)	Aggregated information - Aggregated volume - Price	Weighted average price of 15.56 per share
e)	Date of the transaction	22 December 2017
f)	Place of the transaction	Off Market

Contacts

Creo Medical:	Cenkos:	FTI Consulting:
Richard Rees [phone] [e-mail]	Camilla Hume/Mark Connelly (NOMAD) Michael Johnson / Russell Kerr (Sales) [phone]	Brett Pollard / Mo Noonan [phone] [e-mail]

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring the CROMA surgical system to market through a suite of medical instruments which the Company has designed, initially for GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

 

END

 

 

DSHLLFIFFELFFID